One stock that has been catching fire in recent action Propanc Biopharma Inc (OTCMKTS:PPCB). The stock is up as much as 1,900% in just the past 5 days. The move appears to be powered by factors other than necessarily purely market-driven issues, but there is an interesting narrative here to appreciate.
In any case, the company just announced that it has been selected to present at the prestigious 25th Annual NewsMakers in the Biotech Industry on Friday, September 7th, at 2:00 pm, ET, at the Millennium Broadway Hotel and Conference Center in New York. The recent run higher is in advance of this appearance, which will take place this week.
Propanc Biopharma Inc (OTCMKTS:PPCB) trumpets itself as a development stage healthcare company that focuses on the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia.
The company’s lead product is PRP, a formulation that is in a preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes acting synergistically.
In short, Propanc Biopharma is a biopharmaceutical company developing new cancer treatments for solid tumors. The company has developed a formulation of anti-cancer compounds designed to control or prevent tumors from recurring and spreading throughout the body using proenzymes, which are inactive precursors of enzymes.
The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was founded in 2007 and is based in Camberwell, Australia.
According to company materials, “Propanc Biopharma is a biopharmaceutical company developing new cancer treatments initially for patients suffering from pancreatic, ovarian and colorectal cancers. We have developed a formulation of anti-cancer compounds, which exert a number of effects designed to control or prevent tumors from recurring and spreading throughout the body by targeting and eradicating cancer stem cells. Our products involve or employ pancreatic proenzymes, which are inactive precursors of enzymes. In the near term, we intend to target patients with limited remaining therapeutic options for the treatment of solid tumors. In future, we intend to develop our lead product candidate to treat (i) early-stage cancer and (ii) pre-cancerous diseases and (iii) as a preventative measure for patients at risk of developing cancer based on genetic screening.”
Find out when $PPCB reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
As noted above, the stock has been on fire. In all, recent action has seen just under 1900% added to share values of the company over the past week of action, a bounce that has taken root amid largely bearish action over the larger time frame. In addition, the listing has seen interest climb, with an increase in recent trading volume of 850% above the average volume levels in play in this stock over the longer term.
“We are very proud to have been selected by BioCentury to present at NewsMakers in the Biotech Industry. It gives us a great opportunity to convey our story to international investors,” said James Nathanielsz, Propanc Biopharma’s Chief Executive Officer. “Our focus will be to present the recent advancements of our lead product candidate, PRP, and its effects against cancer stem cells as a way to control metastasis, which is the main cause of patient death from cancer.”
Note, to reiterate: the style of action and some of the message board and associated press materials we have seen carry the fingerprint of something other than purely organic market action, so it may be wise to address this one with a grain of healthy skepticism.
At this time, carrying a capital value in the market of $6.51M, PPCB has virtually no cash on the books, which compares with about $6.9M in total current liabilities. The company is pre-revenue at this point. This is an exciting story, and we look forward to a follow-up chapter as events transpire. Sign-up for continuing coverage on shares of $PPCB stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!
Disclosure: we hold no position in $PPCB, either long or short, and we have not been compensated for this article.